Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Treatment of occipital neuralgia using onabotulinum toxin A

2021; Wiley; Volume: 145; Issue: 2 Linguagem: Inglês

10.1111/ane.13533

1600-0404

Isabela Maria Garcia Marcolla, Carlos Henrique Ferreira Camargo, Léo Coutinho, Matheus Gomes Ferreira, Alex Tiburtino Meira, Élcio Juliato Piovesan, Hélio Afonso Ghizoni Teive,

Pain Mechanisms and Treatments

To determine the effectiveness of botulinum toxin in a sample of patients diagnosed with greater occipital nerve neuralgia.Twenty-nine patients (28 females, 1 male) were treated for greater occipital nerve neuralgia with onabotulinum toxin type A; the Visual Analog Pain Scale was used to determine pain severity at treatment and again 12 weeks after application.Average doses of onabotulinum toxin type A of 18.66±6.44 U per nerve and 35.96±12.89 U per patient were utilized. Average pain severity among the sample was 9.81±0.89 prior to botulinum toxin application and 3.68±2.31 points (p<0.0001) twelve weeks after application. Pain frequency decreased from 29.93±0.37 to 12.17±11.05 days with pain per month (p<0.0001). Six patients reported absence of pain after application (p=0.023). Dose did not correlate with the degree of clinical response observed, and no side effects were reported.Our findings suggest onabotulinum toxin type A is a safe and effective treatment alternative for patients suffering from refractory greater occipital nerve neuralgia.